Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?

NCT01705171 | Completed

• 2 other identifiers: GGP1345012GLUT5
• Study Type: observational
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

In this study we will investigate the expression of the fructose transport protein GLUT5 in the small intestine in patients with functional GI disoders and fructose intolerance compared to matched healthy controls.

Conditions

Irritable Bowel Syndrome; Fructose Intolerance

Keywords

IBS; fructose intolerance; GLUT 5; GLUT 2

Outcome Measures

Primary Outcomes (1)

• mRNA and protein expression of Glut5

  on day of endoscopy

Secondary Outcomes (1)

• mRNA and protein expression of Glut2

  on day of endoscopy

Study Arms (2)

IBS patients with fructose intolerance

analysis of biopsies

Control group: no IBS or fructose intolerance

analysis of biopsies

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients referred to our practice for evaluation of symptoms consistent with FGID undergoing upper GI endoscopy with biopsy and fructose breath testing as part of their usual clinical evaluation.

You may qualify if:

• Patients referred to our practice for evaluation of symptoms consistent with FGID undergoing upper GI endoscopy with biopsy and fructose breath testing as part of their usual clinical evaluation. Male or female patients aged between 18 and 60 years with FGID (Irritable Bowel Syndrome (IBS), Functional Dyspepsia (FD) or Functional Bloating (FB), as defined by Rome III criteria.
• Successive patients without fructose intolerance undergoing upper GI endoscopy for other reasons without inflammatory disease

You may not qualify if:

• Inflammatory GI disease, coeliac's disease, other relevant systemic disorders as judged by investigator, concomitant antiinflammtory treatments, absent informed consent.

Sponsors & Collaborators

• Brain-Gut Research Group: lead

Study Sites (1)

Gastoenterology Group Practice

Bern, Switzerland

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome; Fructose Intolerance

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Fructose Metabolism, Inborn Errors; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• C Wilder-Smith, MD

  Brain-Gut Research Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr. med.

Study Record Dates

• First Submitted: October 9, 2012
• First Posted: October 12, 2012
• Study Start: December 1, 2011
• Primary Completion: May 1, 2013
• Study Completion: October 1, 2013
• Last Updated: December 17, 2018

Record last verified: 2018-12

Locations

CH (1)